These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9105227)

  • 21. Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: application to moxonidine.
    Trocóniz IF; de Alwis DP; Tillmann C; Callies S; Mitchell M; Schaefer HG
    Clin Pharmacol Ther; 2000 Jul; 68(1):18-27. PubMed ID: 10945312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are plasma concentration values necessary for pharmacodynamic modeling of muscle relaxants?
    Fisher DM; Wright PM
    Anesthesiology; 1997 Mar; 86(3):567-75. PubMed ID: 9066322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
    Trocóniz IF; Naukkarinen TH; Ruottinen HM; Rinne UK; Gordin A; Karlsson MO
    Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential allocation trial design in anesthesia: an introduction to methods, modeling, and clinical applications.
    Görges M; Zhou G; Brant R; Ansermino JM
    Paediatr Anaesth; 2017 Mar; 27(3):240-247. PubMed ID: 28211193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.
    Pai SM; Girgis S; Batra VK; Girgis IG
    AAPS J; 2009 Sep; 11(3):535-40. PubMed ID: 19629711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acetaminophen, ibuprofen, and tramadol analgesic interactions after adenotonsillectomy.
    Hannam JA; Anderson BJ; Potts A
    Paediatr Anaesth; 2018 Oct; 28(10):841-851. PubMed ID: 30117229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using probit regression to disclose the analytical performance of qualitative and semi-quantitative tests.
    Åsberg A; Johnsen H; Mikkelsen G; Hov GG
    Scand J Clin Lab Invest; 2016 Nov; 76(7):515-519. PubMed ID: 27385434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two-dose technique to create an individual dose-response curve for atracurium.
    Meretoja OA; Wirtavuori K
    Anesthesiology; 1989 May; 70(5):732-6. PubMed ID: 2719305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.
    Mick R; Ratain MJ
    Cancer Chemother Pharmacol; 1993; 33(1):1-9. PubMed ID: 8269582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface activities of tertiary amine local anesthetics at air/water interface in the presence and absence of phospholipid monolayers.
    Lin HC; Ueda I; Lin SH; Shieh DD; Kamaya H; Eyring H
    Biochim Biophys Acta; 1980 May; 598(1):51-65. PubMed ID: 7417430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-response regressions for algal growth and similar continuous endpoints: calculation of effective concentrations.
    Christensen ER; Kusk KO; Nyholm N
    Environ Toxicol Chem; 2009 Apr; 28(4):826-35. PubMed ID: 19391676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.
    Keall PJ; Webb S
    Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishing cut-offs for urine erythrocyte and leukocyte dipstick tests.
    Chung Y; Ko DH; Hyun J; Kim HS; Park MJ; Shin DH
    Scand J Clin Lab Invest; 2018 Jul; 78(4):301-304. PubMed ID: 29667904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is the assumption of normality or log-normality for continuous response data critical for benchmark dose estimation?
    Shao K; Gift JS; Setzer RW
    Toxicol Appl Pharmacol; 2013 Nov; 272(3):767-79. PubMed ID: 23954464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic parameter estimation: population size versus number of samples.
    Girgis S; Pai SM; Girgis IG; Batra VK
    AAPS J; 2005 Oct; 7(2):46. PubMed ID: 16353905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacodynamic modeling and covariate detection for central neural blockade.
    Schnider TW; Minto CF; Bruckert H; Mandema JW
    Anesthesiology; 1996 Sep; 85(3):502-12. PubMed ID: 8853080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data.
    Wyska E; Mager DE; Krzyzanski W
    J Pharm Sci; 2003 Jul; 92(7):1438-54. PubMed ID: 12820148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.